There was no statistically significant difference in age, percentage of males, baseline Eastern Cooperative Oncology Group (ECOG) score, cancer treatment, NT‐proBNP, D‐dimer, NLR, conduction disorder on ECG (including bundle branch blocks and atrioventricular blocks), decreased LVEF on TTE, Albumin/globulin, AST/ALT, LDL/HDL, non‐cardiac immune‐related adverse events, or past comorbidities between the two groups (Table 2). This evidence concerns the gene ALB and conduct disorder.